Search

Author/Creator Lawitz, E.

1. A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. Issue 12 (16th July 2015)

Authors:
Lawitz, E.; Freilich, B.; Link, J.; German, P.; Mo, H.; Han, L.; Brainard, D. M.; McNally, J.; Marbury, T.; Rodriguez‐Torres, M.
Journal:
Journal of viral hepatitis
Issue:
Volume 22:Issue 12(2015)
Page Start:
1011
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. Issue 8 (15th December 2014)

Authors:
Tatum, H.; Thuluvath, P. J.; Lawitz, E.; Martorell, C.; DeMicco, M.; Cohen, S.; Rustgi, V.; Ravendhran, N.; Ghalib, R.; Hanson, J.; Zamparo, J.; Zhao, J.; Cooney, E.; Treitel, M.; Hughes, E.
Journal:
Journal of viral hepatitis
Issue:
Volume 22:Issue 8(2015)
Page Start:
658
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. Issue 6 (6th February 2018)

Authors:
Sulkowski, M. S.; Feld, J. J.; Lawitz, E.; Felizarta, F.; Corregidor, A. M.; Khalid, O.; Ghalib, R.; Smith, W. B.; Van Eygen, V.; Luo, D.; Vijgen, L.; Gamil, M.; Kakuda, T. N.; Ouwerkerk‐Mahadevan, S.; Van Remoortere, P.; Beumont, M.
Journal:
Journal of viral hepatitis
Issue:
Volume 25:Issue 6(2018)
Page Start:
631
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study. Issue 8 (9th March 2016)

Authors:
Rodriguez‐Torres, M.; Glass, S.; Hill, J.; Freilich, B.; Hassman, D.; Di Bisceglie, A. M.; Taylor, J. G.; Kirby, B. J.; Dvory‐Sobol, H.; Yang, J. C.; An, D.; Stamm, L. M.; Brainard, D. M.; Kim, S.; Krefetz, D.; Smith, W.; Marbury, T.; Lawitz, E.
Journal:
Journal of viral hepatitis
Issue:
Volume 23:Issue 8(2016)
Page Start:
614
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Randomised clinical study: GR‐MD‐02, a galectin‐3 inhibitor, vs. placebo in patients having non‐alcoholic steatohepatitis with advanced fibrosis. Issue 11 (24th October 2016)

Authors:
Harrison, S. A.; Marri, S. R.; Chalasani, N.; Kohli, R.; Aronstein, W.; Thompson, G. A.; Irish, W.; Miles, M. V.; Xanthakos, S. A.; Lawitz, E.; Noureddin, M.; Schiano, T. D.; Siddiqui, M.; Sanyal, A.; Neuschwander‐Tetri, B. A.; Traber, P. G.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 44:Issue 11/12(2016)
Page Start:
1183
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease. Issue 4 (23rd November 2016)

Authors:
Lawitz, E.; Poordad, F.; Gutierrez, J. A.; Kakuda, T. N.; Picchio, G.; Beets, G.; Vandevoorde, A.; Van Remoortere, P.; Jacquemyn, B.; Luo, D.; Ouwerkerk‐Mahadevan, S.; Vijgen, L.; Van Eygen, V.; Beumont, M.
Journal:
Journal of viral hepatitis
Issue:
Volume 24:Issue 4(2017)
Page Start:
287
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3. Issue 2 (27th November 2017)

Authors:
Younossi, Z. M.; Stepanova, M.; Jacobson, I. M.; Asselah, T.; Gane, E. J.; Lawitz, E.; Foster, G. R.; Roberts, S. K.; Thompson, A. J.; Willems, B. E.; Welzel, T. M.; Pearlman, B.; Younossi, I.; Racila, A.; Henry, L.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 47:Issue 2(2018)
Page Start:
259
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results. (February 2020)

Authors:
Lucas, K.J.; Lopez, P.; Lawitz, E.; Sheikh, A.; Aizenberg, D.; Hsia, S.; Bee, G.G. Boon; Vierling, J.; Frias, J.; White, J.; Eguchi, Y.; Lazas, D.; Neff, G.; Yoneda, M.; Augustin, S.; Kim, W.; Loeffler, Y.; Schaefer, F.; Lamle, S.; Martic, M.
Journal:
Digestive and liver disease
Issue:
Volume 52(2020)Supplement 1
Page Start:
e38
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗